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Background: Whether microRNA-130b(miR-130b) can serve as a prognostic biomarker of hepatocellular carcinoma
(HCC) has not been investigated. In the present study, we investigated the feasibility of miR-130b as a novel prognostic
biomarker for HCC.
Methods: We retrospectively investigated 97 patients diagnosed with HCC who underwent routine curative surgery
between May 2007 and July 2012. miR-130b expression in HCC tissues and paired normal adjacent liver tissues was
measured by reverse transcription and real-time PCR (RT-PCR). Survival curves were plotted using the Kaplan-Meier
method and differences in survival rates were analyzed using the log-rank test.
Results: miR-130b expression level was significantly higher in HCC tissues compared with normal adjacent liver tissues
(P < 0.0001). The 5-year overall survival (OS) of high miR-130b expression group was significantly shorter than that of low
miR-130b expression group (43.6% vs. 71.5%; P = 0.022). Moreover, the 5-year disease-free survival (DFS) of high miR-130b
expression group was also significantly shorter than that of low miR-130b expression group (25.9% vs. 63.9%; P = 0.012).
In a multivariate Cox model, we found that miR-130b expression was an independent prognostic factor for both 5-year
OS (hazards ratio [HR] = 2.523, 95% confidence interval [CI] = 1.024-7.901, P = 0.011) and 5-year DFS (HR = 4.003,
CI = 1.578-7.899, P = 0.005) in HCC.
Conclusion: The results indicated that high expression of microRNA-130b was correlated with significant characteristics
of patients with HCC, and it might be useful as a novel prognostic biomarker for HCC.
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Hepatocellular carcinoma (HCC) is the third most com-
mon cause of mortality from cancer worldwide [1]. In
China, HCC is the second highest cancer killer since the
1990s, which alone accounts for 53% of all liver cancer
deaths worldwide [2]. More than 90% of HCC cases de-
velop in chronically inflamed liver as a result of viral hepa-
titis, alcohol abuse and in increasing incidence in patients
with non-alcoholic fatty liver disease [3]. Although the clin-
ical staging systems for HCC have been used in routine
clinical decision making, there is still a need to refine and
complement outcome predictions. Modifications of these* Correspondence: wangwenyaodoctor@126.com
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unless otherwise stated.staging systems by the addition of new biomarkers are likely
to improve the prognostic assessment of HCC patients and
could therefore fulfill a clinical need [4-9].
MicroRNAs (miRNAs) are endogenously expressed,
small interfering RNAs [10]. They are transcribed as pre-
cursor molecules that are subsequently processed into
the active ~21 nucleotide mature miRNAs. The mature
miRNA binds to the 3’untranslated region of the target
mRNA through imperfect base pairing, producing trans-
lational arrest and/or degradation of the mRNA. A
growing number of both direct and indirect evidence
suggests a relationship between differential miRNA ex-
pression and cancer [11,12]. miR-130b has been found
to be deregulated in some types of cancers, including be-
ing overexpressed in gastric cancer [13,14], glioma [15],td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,













<50 46 25 21
≥50 51 23 28 0.81
Gender
Male 59 29 30
Female 38 19 19 0.85
HBsAg
Postive 61 20 41
Negtive 36 28 8 0.02
AFP (ng/ml)
<25 48 38 10
≥25 49 10 39 0.04
Tumor size (cm)
<5 52 40 12
≥5 45 8 37 0.04
Histologic grade
High 33 4 29
Low 64 44 20 0.005
Tumor number
Solitary 61 34 27
Multiple 36 14 22 0.08
Vein invasion
Presence 36 17 19
Absence 61 31 30 0.41
TNM stage
I-II 52 44 8
III–IV 45 4 41 <0.001
AFP = a-fetoprotein.
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lated in endometrial cancer [17] and papillary thyroid
carcinoma [18]. Previously, Liu et al. reported that the ex-
pression level of miR-130b was upregulated in HCC tissues.
Furthermore, circulating miR-130b in serum was a bio-
marker with clinical value for HCC screening [19].
However, whether miR-130b can serve as a prognostic
biomarker of HCC has not been investigated. Therefore, in
the present study, we investigated the feasibility of miR-
130b as a novel prognostic biomarker for HCC.
Methods
Patients and tissue samples
We retrospectively investigated 97 patients diagnosed with
HCC who underwent routine curative surgery between
May 2007 and July 2012 at The Second Hospital of hebei
Medical university. None of the patients received radiother-
apy or chemotherapy before surgery. For each case, the
diagnosis and the histologic grade were confirmed by two
pathologists. The fresh human HCC tissues and paired nor-
mal adjacent liver tissues were obtained from each HCC
patients. Tissues were snap frozen in liquid nitrogen after
surgical resection until use. Followup included serum a-
fetoprotein (AFP) level, abdominal ultrasonography, and
chest radiography every 1–3 months after curative hepatec-
tomy. When tumor recurrence was suspected, computed
tomography scan (CT) or/and magnetic resonance imaging
scan (MRI) was performed to confirm the diagnosis. The
clinico-pathological features of the patients were summa-
rized in Table 1. The present study was approved by the Re-
search Ethics Committee of The Second Hospital of hebei
Medical university. Informed consent was obtained
from all the patients. All specimens were handled and
made anonymous according to the ethical and legal
standards.
Isolation of total RNA and real-time PCR analysis
MiR-130b expression level in HCC tissues and paired nor-
mal adjacent tissues was measured by reverse transcription
and real-time PCR (RT-PCR). Total RNA was isolated from
frozen samples using Trizol reagent (Invitrogen, CA,
U.S.A.) according to the manufacturer’s protocol. The
TaqMan microRNA assay and TaqMan universal PCR
master mix were used to detect the expression of miR-
130b, and the U6 gene was used as an internal control
to normalize variances. Relative quantification of target
miRNA expression was evaluated using the comparative
cycle threshold (CT) method. Each sample was examined
in triplicate and the raw data were presented as the relative
quantity of target miRNA, normalized with respect to U6.
Statistical analysis
The Mann–Whitney test or Kruskal–Wallis was performed
to determine the significance of miRNA levels. Survivalcurves were plotted using the Kaplan-Meier method and
differences in survival rates were analyzed using the log-
rank test. Prognostic relevance of each variable to overall
survival (OS) and disease-free survival (DFS) were analyzed
using the Cox regression model. Multivariate analysis of the
prognostic factors was performed with Cox regression
model. P < 0.05 was considered statistically significant. All
statistical calculations were performed using SPSS 18.0 for
Windows (SPSS Inc, IL, USA).
Results
miR-130b was significantly upregulated in HCC tissues
We analyzed the expression levels of miR-130b in 97
pairs of HCC tissues and normal adjacent tissues from
97 HCC patients. As revealed by quantitative RT-PCR
Figure 1 The relative expression level of miR-130b in human HCC
tissues (n = 97) and matched adjacent noncancerous liver tissues
(n = 97). miR-130b expression was significantly higher in HCC tissues
(median expression level: 1.90, range 0.65–7.68) compared with
normal adjacent liver tissues (median relative expression level: 0.58,
range 0.03–3.90; p < 0.0001)
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in HCC tissues (median expression level: 1.90, range 0.65–
7.68) compared with normal adjacent liver tissues (median
relative expression level: 0.58, range 0.03–3.90; P < 0.0001,
Figure 1).Figure 2 Kaplan-Meier curves of the overall survival of 97 HCC patien
significantly lower than that in patients with low miR-130b expression.Association between miR-130b expression and the clinico-
pathological features of HCC
For better understanding of the clinical relevance of
miR-130b expression in HCC, we divided the 97 HCC
patients into a high expression group (n =49) and a low
expression group (n =48), according to the median ex-
pression level of miR-130b (1.90) in all HCC samples.
And, the relationships of the miR-130b with various clin-
ical features of HCC were analyzed and summarized in
Table 1. The results revealed that a high level of miR-
130b expression was correlated with serum a-fetoprotein
(AFP) level (P = 0.04), HBsAg status (P =0.02), tumor
size (P = 0.04), high histologic grade (P =0.005), and high
TNM stage (p < 0.001). However, there were no signifi-
cant correlations of miR-130b expression with other
clinical features such as gender, age, vein invasion, and
tumor number(all P > 0.05).
Prognostic values of miR-130b expression in HCC
To further investigate the correlations of miR-130b expres-
sion level with survival of patients with HCC, Kaplan-
Meier analyses were performed. As shown in Figure 2, the
5-year OS of high miR-130b expression group was signifi-
cantly shorter than that of low miR-130b expression group
(43.6% vs. 71.5%; P = 0.022). Moreover, the 5-year DFS of
high miR-130b expression group was also significantlyts. Overall survival rate in patients with high miR-130b expression was
Figure 3 Kaplan-Meier curves of the disease-free survival of 97 HCC patients. Disease-free survival rate in patients with high miR-130b expression
was significantly lower than that in patients with low miR-130b expression.
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http://www.diagnosticpathology.org/content/9/1/160shorter than that of low miR-130b expression group (25.9%
vs. 63.9%; P = 0.012, shown in Figure 3). Furthermore, in
a multivariate Cox model, we found that miR-130b expres-
sion was an independent poor prognostic factor for both
5-year OS (hazards ratio [HR] = 2.523, 95% confidence
interval [CI] = 1.024-7.901, P = 0.011, Table 2) and 5-year
DFS (HR = 4.003, CI = 1.578-7.899, P = 0.005, Table 2) in
HCC.Table 2 Multivariate analysis of the associations of prognosis
expression in HCC patients
Overall survival




AFP level 2.119 0.981-5.889
Tumor size 3.121 0.478-7.889
Histologic grade 4.891 2.113-5.991
Tumor number 2.997 0.912-3.091
Vein invasion 1.982 0.891-1.971
TNM stage 2.131 1.091-6.901
miR-130b expression 2.523 1.024-7.901
AFP = a-fetoprotein; CI = confidence interval; HR = hazards ratio.Discussion
A growing number of novel treatment strategies have been
developed for HCC, including molecular targeted therapy,
gene therapy, and immunotherapy. However, satisfactory
therapeutic outcomes have not been achieved, and the sur-
vival rate of HCC is still low. A complete understanding of
the molecular mechanisms underlying tumor initiation and
progression is essential for novel prognostic and therapeuticwith various clinicopathologic parameters and miR-130b
Disease-free survival
P value HR 95% CI P value
0.41 0.827 0.461-1.251 0.39
0.56 0.914 0.671-1.889 0.52
0.12 2.121 0.871-5.113 0.14
0.11 3.671 0.367-12.112 0.23
0.34 4.116 0.781-11.234 0.31
0.04 5.995 3.467-8.114 0.01
0.13 3.111 0.872-9.112 0.09
0.09 2.891 0.781-5.997 0.08
0.009 4.121 1.341-7.113 0.007
0.011 4.003 1.578-7.889 0.005
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tients with HCC. Over the last years, miRNAs are
emerging as a new class of gene regulators involved in
different malignancies.
The miR-130 family is formed by mature miR-130a
and miR-130b that share the same seed sequence and
are coded by two independent loci (miRBase Database).
miR-130 has been found to linked to mesenchymal dif-
ferentiation, immune cell function, and hypoxic response
modulation [20]. miR-130 has also been validated as a
peroxisome proliferator–activated receptor γ (PPARγ)
regulator because it suppresses the adipogenic process
through the binding to two distinct highly conserved
sites located in the coding sequence and 3’UTR of the
corresponding mRNA [20,21]. miR-130b has been found
to be deregulated in some types of cancers, including be-
ing overexpressed in gastric cancer [13,14], glioma [15],
and RCC [16], while being downregulated in endomet-
rial cancer [17] and papillary thyroid carcinoma [18]. For
example, Zhao et al. demonstrated that the deregulated
expression of miR-130b was associated with poor prog-
nosis and aggressive phenotype of pancreatic cancer, and
miR-130b played an important role in the regulation of
pancreatic cancer malignant behavior including cell pro-
liferation and invasion by directly targeting STAT3, indi-
cating that miR-130b might be applied as a potential
prognostic biomarker and inhibitor in pancreatic cancer
[22]. Previously, Liu et al. reported that the expression
level of miR-130b was upregulated in HCC tissues.
Furthermore, circulating miR-130b in serum was a
biomarker with clinical value for HCC screening [19].
However, whether miR-130b can serve as a prognostic
biomarker of HCC has not been investigated. Therefore,
we investigated the feasibility of miR-130b as a novel
prognostic biomarker for HCC.
In the present study, our results showed that miR-
130b expression was significantly higher in HCC tissues
compared with normal adjacent liver tissues. The rela-
tionships of the miR-130b with various clinical features
of HCC were analyzed. The results revealed that a high
level of miR-130b expression was correlated with serum
AFP level, HBsAg status, tumor size, high histologic
grade, and high TNM stage, suggesting that miR-130b
might be involved in the carcinogenesis and metastasis
of HCC. Furthermore, the 5-year OS of high miR-130b
expression group was significantly shorter than that of
low miR-130b expression group. Moreover, the 5-year
DFS of high miR-130b expression group was also signifi-
cantly shorter than that of low miR-130b expression
group. In a multivariate Cox model, we found that miR-
130b expression was an independent poor prognostic
factor for both 5-year OS and 5-year DFS, indicating
that high miR-130b level might be a promising non-
invasive biomarker for prognosis of patients with HCC.Conclusion
In conclusion, we demonstrated that miR-130b was sig-
nificantly upregulated in HCC and correlated with
poorer patients’ prognosis and it might be useful as a
prognostic biomarker for HCC.
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